Loading clinical trials...
Loading clinical trials...
An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Conditions
Interventions
Cytarabine and Idarubicin
CPX-315
Locations
30
France
CHU Amiens Picardie site Sud
Amiens, France
CH Avignon
Avignon, France
CHRU Jean Minjoz
Besançon, France
Centre Hospitalier de Béziers
Béziers, France
Hôpital Avicenne APHP
Bobigny, France
Institut d'hématologie de Basse Normandie (IHBN)
Caen, France
Start Date
May 3, 2023
Primary Completion Date
October 1, 2027
Completion Date
October 1, 2027
Last Updated
January 30, 2024
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06994676
NCT06484062
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions